Intravenous administration of anakinra in children with macrophage activation syndrome.
Omkar K PhadkeKelly Rouster-StevensHelen GiannopoulosShanmuganathan ChandrakasanSampath PrahaladPublished in: Pediatric rheumatology online journal (2021)
Intravenous administration of anakinra is an important therapeutic option for critically ill patients with MAS/HLH. It is also beneficial for those with thrombocytopenia, subcutaneous edema, neurological dysfunction, or very young, hospitalized patients who need multiple painful subcutaneous injections.